

NJC

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.


Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/njc



This paper proposed a novel strategy of screening anti-diabetic compounds by HSCCC coupled with post-column on-line α -amylase evaluation.

1 **Efficient method for screening and identification of anti-diabetic**
2 **components in the leaves of *Olea europaea* L.**

3
4 Jia Zhang^a, Xinyi Huang^{a*}, Xiaoming Sun^a, Dong Pei^{a, b}, Duolong Di^{a, b*}

5 *^aKey Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural*
6 *Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of*
7 *Sciences, Lanzhou 73000, China*

8 *^bCenter of Resource Chemical and New Material, Lanzhou Institute of Chemical Physics, Chinese*
9 *Academy of Sciences, Qingdao 266100, China*

10 *Corresponding author E-mail address: didl@licp.cas.cn (Duolong Di); huangxy003@gmail.com*
11 *(Xinyi Huang)*

12
13
14 **Abstract**

15 In this article, an efficient method, high speed counter-current chromatography
16 (HSCCC) coupled with post-column on-line evaluation was developed to screen,
17 isolate and identify the major anti-diabetic compounds in the leaves of *Olea europaea*
18 L. The HSCCC separation employed a two-step process: first, an optimized two-phase
19 system that composed of ethyl acetate-water (1:1) was used to separate the extraction;
20 then, a solvent system that composed of butanol-water-acetic acid (1:1:0.1) was
21 applied to the further separation of the anti-diabetic active compounds. The eluant
22 was detected by post-column evaluation with α -amylase on both steps. It was found

23 that five major constituents in the extract of the leaves of *O. europaea* L possessed
24 potential anti-diabetic activities. Their structures were identified as Oleuropein,
25 Ligstroside, Hydroxytyrosol, Tyrosol and Luteolin-7-O- β -D-glucoside by ^1H - and
26 ^{13}C -Nuclear Magnetic Resonance (NMR).

27 **Keywords** Leaves of *Olea europaea* L, Anti-diabete, High speed counter-current
28 chromatography, On-line activity screening

29

30 **1 Introduction**

31 The Olive tree (*Olea europaea* L.) is one of the very important fruit trees in
32 Mediterranean countries. Epidemiological studies have shown a relationship between
33 the Mediterranean diet and a lowered incidence of pathologies such as cardiovascular
34 diseases, cancer and diabetes¹. Several studies attribute these health benefits to high
35 consumption of virgin olive oil which is rich in phenols and flavonoids as well as
36 other typical components of the Mediterranean diet². Many data on the polyphenols of
37 olive fruits³ and olive oil⁴ have been reported, but a few studies have been published
38 on olive leaves^{5, 6}. In fact, olive leaves which are considered as byproduct of olive
39 trees are the best source of oleuropein and related compounds. Those compounds
40 have been shown to have multifunctional bioactive properties related to radical
41 scavenging activity^{7, 8}. Meanwhile, olive leaves were used to treat and prevent
42 hypertension in popular medicine and phytotherapy. And there has report that the
43 leaves also have the activity of anti-diabetics, but the active ingredients are often
44 difficult to separate and purify directly from crude extracts due to their high polarity.


45 Diabetes mellitus is one of the global major diseases. The World Health
46 Organization (WHO) estimated that there are 346 million people worldwide who
47 suffer from diabetes, and this figure will double by the year 2030. Diabetes is a group
48 of metabolic diseases but the predicted increase is mainly in type II diabetes⁹. Type
49 II diabetes mellitus, by far the most common type, is a metabolic disorder of
50 multiple etiology characterized by carbohydrate, lipid and protein metabolic disorders.
51 And it includes defects in insulin secretion, almost always with a major contribution
52 of insulin resistance¹⁰. These abnormalities could lead to many lesions, such as
53 retinopathy, nephropathy, neuropathy and angiopathy¹¹. Consequently, the inhibition
54 of carbohydrate digestive enzymes is considered a therapeutic tool for the treatment of
55 type II diabetes¹². The most important digestive enzyme is pancreatic α -amylase, a
56 calcium metalloenzyme that catalyzes the hydrolysis of the α -1, 4 glycosidic linkages
57 of starch, amylose, amylopectin, glycogen and various maltodextrins. Furthermore, it
58 is responsible of most of starch digestion in humans¹³. Thus, the inhibition of
59 α -amylase activity is considered as an effective strategy to control diabetes because
60 the inhibitors of α -amylase are effective in delaying glucose absorption by means of
61 breaking down long-chain carbohydrates. From this point of view, more researchers
62 have focused on the search for more effective inhibitors of α -amylase from natural
63 materials for anti-diabetes^{14,15}, such as polysaccharides from tea leaves¹⁶, hydrolysate
64 from sardine muscle and isoflavones from soybean¹⁷.

65 It is a time-consuming and hard work to screen the natural hypoglycemic agents
66 from complex mixtures. HSCCC is now accepted as one of the common techniques

67 for the separation and purification of various compounds from natural products¹⁸.
68 HSCCC is a liquid chromatography working without a solid stationary phase and it
69 has the ability of large-scale purification¹⁹. As we know, in order to obtain a suitable
70 two-phase system for HSCCC, the polarities of the solvents chosen should be differ
71 significantly and n-butanol/water is one of the most polar solvent systems for the
72 separation.

73 Thus, in this study, different fractions I -VI were obtained by reflux extraction and
74 separated with macroporous resins from the leaves of *Olea europaea* L. Then, the
75 α -amylase system was used to evaluate the inhibitive effects for anti-diabetic
76 activities of the 6 fractions. The results showed that the fraction IV has a better
77 anti-diabetic effect than other fractions. We proposed a novel strategy of HSCCC
78 purification for the efficient and effective discovery of anti-diabetic compounds from
79 fraction IV based on a post-column on-line method with anti-diabetic assay by
80 α -amylase. The separation contained two steps: at first, an optimized two-phase
81 system that composed of ethyl acetate–water (1:1) was used to separate the extraction;
82 then, a solvent system composed of butanol–water–acetic acid (1:1:0.1) was applied
83 to the further separation of the anti-diabetes active components. The eluant was
84 evaluated by post-column on-line evaluation with α -amylase anti-diabetic assay on
85 both steps. We found that there have five major constituents in the extract of the
86 leaves of *O. europaea* L possessed potential anti-diabetes activities. Their structures
87 were identified as Oleuropein, Ligstroside, Hydroxytyrosol, Tyrosol,
88 Luteolin-7-O- β -D-glucoside by ¹H-NMR and ¹³C-NMR (Fig.1). In this way, a method

89 which is combination of liquid-liquid partition chromatography and α -amylase on-line
90 evaluation was accomplished to screening the anti-diabetic compounds. And the
91 method would make it possible to use HSCCC for the preparative isolation and
92 screening of the anti-diabetic high polarity compounds from *Olea europaea* L.



99 Fig.1 Structures of the anti-diabetic compounds: (A) Oleuropein, (B) Ligstroside, (C)
100 Hydroxytyrosol, (D) Tyrosol, (E) Luteolin-7-O- β -D-glucoside.

101

102 2 Experimental

103 2.1 Apparatus

104 In the present study, a Spectrum HSCCC instrument (DE Spectrum Centrifuge)
105 (Dynamic Extractions Co. Ltd., Slough, UK) equipped with two bobbins was
106 employed. Each bobbin of the apparatus fits one analytical column and one
107 preparative column made by polytetrafluoroethylene (PTFE). The column volume of

108 each analytical column and preparative column is 14.0 mL of 0.8 mm ID and 72.0 mL
109 of 1.6 mm ID, respectively. The β -value is defined as $\beta = r/R$, where r is the rotation
110 radius or the distance from the coil to the holder shaft, and R is the revolution radius
111 or the distances between the holder axis and central axis of the centrifuge. In this case,
112 β varied from 0.64 at the internal terminal to 0.81 at the external terminal for the
113 analytical columns, and it is 0.52 to 0.86 for preparative columns. The maximum
114 rotational speed of the instrument is limited to 1600 rpm. A rotation rate of 1400 rpm
115 was used in this study giving a high “g” value of $240 \times g$. The HSCCC separation
116 setup consisted of two preparative pumps H&E P3000 A, and a spectrophotometer
117 H&E UV3000 (H&E Co. Ltd., Beijing, China) with a preparative cell operating at
118 280 nm. The separation temperature was controlled by a DLSB-10/40°C constant
119 temperature regulator (Yarong Instruments Co. Ltd., Zhengzhou, China). A CBS-A
120 automatic fraction collector (Shanghai Huxi Analysis Instrument Factory Co. Ltd.,
121 Shanghai, China) was used to collect the fraction.

122 The HPLC analysis was performed in an Agilent 1200 Series (Agilent Technologies,
123 Palo Alto, CA, USA) LC system, which was equipped with a G1322A vacuum
124 degasser, a G1311 A quaternary pump, a G1315B diode array detector (DAD)
125 performing the wavelength scanning from 190 to 950 nm and a G1328B manual
126 injection valve. The system was controlled by Agilent Chemstation software (version
127 A.10.02) (Agilent Technologies, Palo Alto, CA, USA). The separation was achieved
128 on a Sinochrom ODS-AP C₁₈ analytical column (Dalian Elite Analytical Instruments
129 Co., Dalian, China, 250×4.6 mm i.d., 5 μ m).

130 The ^1H -NMR and ^{13}C -NMR spectra were recorded on Varian Inova-400 FT-NMR
131 spectrometer (400 and 100 MHz, respectively).

132

133 **2.2 Reagents and Samples**

134 α -amylase from *Bacillus licheniformis*, 4-nitrophenyl α -D-glucopyranoside, dimethyl
135 sulfoxide and starch were purchased from Shanghai Baoman Biological Technology
136 Co. (Shanghai, China). Analytical-grade methanol, acetic acid, ethyl acetate and
137 butanol were purchased from Tianjin Chemical Reagent Corporation (Tianjin, China).
138 Deionized water and the solvents used for the activity screening method were filtered
139 and degassed by passing through a 0.45 μm membrane filter before use. All organic
140 solvents used for extraction and the HSCCC separation were of analytical grade and
141 glass-distilled prior to use.

142 The leaves of *O. europaea* L. were collected in the city of Longnan, Gansu Province,
143 China. The plant was identified by Professor Huanyang Qi in Lanzhou Institute of
144 Chemical Physics, Chinese Academy of Sciences, Lanzhou, China and a voucher
145 specimen was deposited at Key Laboratory for Natural Medicine of Gansu Province,
146 Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, China.

147 Macroporous resin AB-8 was purchased from Sunresin Technology Co. Ltd (Xi'an,
148 China); the resin was pretreated by soaking in ethanol for 24 h, and then washed with
149 ethanol until there was no turbidity when a threefold volume of water was added into
150 the eluent. The resin was subsequently washed with distilled water until the ethanol
151 was thoroughly replaced by the distilled water before use.

152

153 2.3 Sample preparation

154 The dried sample (approximately 250 g) was refluxed with 2.5 L 60% ethanol for 1 h
155 and repeated twice. The combined extracts were evaporated by a rotary evaporator in
156 vacuo at temperature not higher than 50°C. Then the residue was dissolved in a 1000
157 mL volumetric flask with water. The total extraction was named fraction I .

158 Then this solution was divided into five parts, each 150 mL, then subjected to the
159 adsorption procedure for five columns in parallel, which was carried out in a glass
160 column (20 cm×2 cm i.d.) packed with macroporous resin (AB-8). The first column
161 was washed with distilled water of 6 BV at a flow rate of 3 BV/h. The obtained eluant
162 was evaporated to dryness under reduced pressure, named fraction II . The other
163 columns were first washed with distilled water of 6 BV at a flow rate of 3 BV/h and
164 then eluted with aqueous methanol in different ratios of 6 BV at a flow rate of 3 BV/h.
165 The eluants were evaporated to dryness under reduced pressure, named fraction III,
166 IV, V and VI, respectively.

167

168 2.4 Activity analysis for anti-diabetes

169 It was using α -amylase to screen the anti-diabetes activities fraction in the vitro. The
170 α -amylase inhibitory assay was performed according to the method previously
171 described with slight modification^{20, 21}. The total assay mixture composed of 0.1 mL
172 of α -amylase solution (1 unit/mL, distilled water), 0.15 mL of sample solutions at
173 different concentrations (in 5% DMSO). Following incubation at 37 °C for 10 min

174 and then 0.4 mL of soluble starch (0.4% w/v) in 25 mmol/L sodium phosphate buffer
175 (pH7.0) was added to start the reaction. The reaction was carried out at 37°C for 10
176 min and terminated by addition of 0.3 mL of HCl solution (1.0 mol/L). Next added
177 0.2 mL Iodine solution to the reaction system so that the system has color and diluted
178 reaction liquid volume to 4 mL. The absorbance was measured at 660 nm by UV
179 detection. For all tests, the inhibition assay was performed in triplicate. Inhibition
180 activity of α -amylase was determined by a water-containing control which compared
181 with and calculated by the following equation:

$$182 \quad \alpha\text{-amylase activity inhibition rate} = \frac{(A_A - A_B) - (A_C - A_D)}{(A_A - A_B)} \times 100\%$$

183 where A_A was the optical density of reaction blank, the reaction blank mixture
184 contained the same volume of the buffer solution instead of the sample; A_B was the
185 optical density of the reaction in the presence without α -amylase; A_C was the optical
186 density of the reaction in the presence of both α -amylase and olive sample; A_D was the
187 optical density of the reaction in the presence of olive sample.

188

189 **2.5 Selection of the two-phase solvent system**

190 Successful separation by HSCCC depends on the selection of a suitable two-phase
191 solvent system, which provides an ideal range of the partition coefficient (K) for
192 target compounds. Measurement of K values from crude sample was as follows: crude
193 sample (20 mg) was weighed into a 10 mL test tube and added 5 mL of each phase of
194 a pre-equilibrated two-phase solvent system. The test tube was then shaken vigorously
195 for 10 min to thoroughly equilibrate the sample between the two phases. After settling,

196 1 mL of each phase was transferred to two separate test tubes and evaporated to
197 dryness. The residues were diluted with 1 mL methanol and analyzed by HPLC. The
198 *K* value was expressed as the peak area of target compounds in the upper phase
199 (stationary phase) divided by that in the lower phase (mobile phase).

200

201 **2.6 Preparation of two-phase solvent system and sample solution**

202 In this study, the separation contained two steps. In the first step, the selected
203 two-phase solvent system was composed of ethyl acetate–water with the volume ratio
204 of 1:1 (*v/v*). In the second step, the selected two-phase solvent system was composed
205 of butanol–water–acetic acid with the volume ratio of 1:1:0.1 (*v/v/v*). The solvent
206 mixture was vigorously shaken several times and equilibrated in a separation funnel at
207 room temperature. Then the upper phase and the lower phase were separated and
208 degassed by sonication for 30 min prior to use.

209 The sample solution was prepared by dissolving 120 mg crude sample in 6 mL
210 mixture solution of upper phase and lower phase (1:1 *v/v*) used for HSCCC
211 separation.

212

213 **2.7 HSCCC coupled with α -amylase on-line separation**

214 According to the α -amylase activity result, selected fraction IV had better
215 anti-diabetic activity. Thus, we screened the specific anti-diabetic compounds based
216 on on-line HSCCC method with α -amylase assay. This method was created by adding
217 the α -amylase in the fraction collection tube for the rapid screening of the

218 anti-diabetic compounds in a complex mixture. The separation was carried out on
219 preparative column (142 mL) and contained two steps. In each separation run, the
220 multiple layer coiled column was first entirely filled with the upper phase (stationary
221 phase) of ethyl acetate–water (1:1 v/v) in the head to tail mode. Then the lower phase
222 (mobile phase) of ethyl acetate–water (1:1 v/v) was pumped into the column at a flow
223 rate of 4.8 mL/min while the rotor was rotated at 1400 rpm. When hydrodynamic
224 equilibrium was established, 6 mL of the sample solution (20 mg/mL) was injected
225 into the column through the sample valve. In the first step, the mobile phase of ethyl
226 acetate–water (1:1 v/v) was used and the flow rate was 4.8 mL/min. Through the run,
227 the separation temperature was controlled at 30°C. The effluent from the tail end of
228 the column was continuously monitored at 280 nm with the UV detector. Fraction
229 collection was started at the time of injection. In total, fractions were collected in 2
230 min intervals. These fractions were combined according to their composition and
231 evaporated to dryness in the SpeedVac. Each fraction was evaluated by above method
232 with α -amylase activity method.

233 As the fraction 1 obtained from the first step was admixture, further separation was
234 performed for the second step. Fraction 1 was collected and evaporated under reduced
235 pressure to dryness. The second step was filled with the upper phase (stationary phase)
236 of butanol–water–acetic acid (1:1:0.1 v/v/v) in the head to tail mode. Then the lower
237 phase (mobile phase) of butanol–water–acetic acid (1:1:0.1 v/v/v) was pumped into
238 the column at a flow rate of 3 mL/min while the rotor was rotated at 1500 rpm. When
239 hydrodynamic equilibrium was established, 1 mL of the fraction 1 sample solution

240 (20 mg/mL) was injected into the column through the sample valve. Through the run,
241 the separation temperature was controlled at 20 °C. The effluent from the tail end of
242 the column was continuously monitored at 280 nm with the UV detector and fraction
243 collection was started at the time of injection with 2 min intervals. These fractions
244 were combined according to their composition and evaporate to dryness in the
245 SpeedVac. Each fraction was evaluated by the above method with α -amylase activity
246 method.

247

248 **2.8 HPLC analysis and identification of HSCCC peak fractions**

249 The crude sample and fractions separated by HSCCC were all analyzed by HPLC.
250 The analysis was achieved with SinoChrom ODS-AP C₁₈ analytical column at a
251 temperature of 30°C. The mobile phase consisted of solvent A (water) and B
252 (methanol). A liner gradient elution program was used as follows: 0-20 min,
253 1%-100% B. The flow rate was kept at 1.0 mL/min and the detection wavelength was
254 set at 280 nm. The injection volume was 20 μ L each time and all of the mobile phase
255 was filtered through a 0.45 μ m Millipore filter before use.

256

257 **2.9 Identification of anti-diabete compounds with NMR**

258 A semi-preparative HPLC system was used to isolate the constituents from active
259 fractions. The semi-preparative chromatographic conditions applied to the separations
260 were based on the elution profile observed during the HPLC separation. They were
261 optimized for baseline separation of the compounds. The yield per compound was

262 typically in the milligram range. The $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectral of compounds
263 A-E were recorded on a Varian Inova-400 FT-NMR spectrometer (USA) with
264 $\text{DMSO-}d_6$ as the solvent. Chemical shifts were given on a δ (ppm) scale with
265 tetramethylsilane as the internal standard. These compounds were selected as they are
266 the major anti-diabetic active constituents of olive leaves. Date of each compound
267 given as follows:

268 Oleuropein (A): a yellow gum, $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 5.86 (s, 1H, H-1),
269 7.50 (s, 1H, H-3), 3.85 (m, 1H, H-5), 2.39 (m, 1H, H-6), 5.94 (m, 1H, H-8), 1.63 (d,
270 3H, $J = 6.0$ Hz, H-10), 3.66 (s, 3H, OMe), 4.05 (m, 2H, H-1'), 2.67 (m, 2H, H-2'),
271 6.58 (s, 1H, H-4'), 6.62 (d, $J = 8.0$ Hz, 1H, H-7'), 6.46 (d, $J = 8.0$ Hz, 1H, H-8'), 4.63
272 (d, $J = 8.0$ Hz, 1H, glc-1"); $^{13}\text{C-NMR}$ (100 MHz, $\text{DMSO-}d_6$): δ 92.9 (C-1), 153.3
273 (C-3), 107.7 (C-4), 30.1 (C-5), 39.9 (C-6), 170.7 (C-7), 123.1 (C-8), 128.4 (C-9), 13.0
274 (C-10), 166.2 (C-11), 51.3 (OMe), 65.1 (C-1'), 33.7 (C-2'), 129.1 (C-3'), 116.2 (C-4'),
275 145.1 (C-5'), 143.8 (C-6'), 115.5 (C-7'), 119.6 (C-8'), 99.0 (glc-1"), 73.3 (glc-2"), 76.5
276 (glc-3"), 69.9 (glc-4"), 77.4 (glc-5"), 61.1 (glc-6"). Those data were in agreement with
277 earlier published data for Oleuropein²².

278 Ligstroside (B): a yellow gum, $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 5.91 (s, 1H, H-1),
279 7.47 (s, 1H, H-3), 3.86 (m, 1H, H-5), 2.39 (m, 1H, H-6), 6.01 (m, 1H, H-8), 1.63 (d,
280 3H, $J = 6.0$ Hz, H-10), 3.66 (s, 3H, OMe), 4.19 (m, 2H, H-1'), 2.78 (m, 2H, H-2'),
281 7.05 (d, 3H, $J = 8.8$ Hz, H-4'), 6.76 (d, 3H, $J = 8.0$ Hz, H-5'), 6.76 (d, 1H, $J = 8.0$ Hz,
282 H-7'), 7.05 (d, 1H, $J = 8.8$ Hz, H-8'), 4.84 (d, 1H, $J = 8.0$ Hz, glc-1"); $^{13}\text{C-NMR}$ (100
283 MHz, $\text{DMSO-}d_6$): δ 92.9 (C-1), 152.8 (C-3), 107.3 (C-4), 29.8 (C-5), 33.8 (C-6),

284 170.4 (C-7), 122.6 (C-8), 127.7 (C-9), 11.9 (C-10), 165.7 (C-11), 50.0 (OMe), 64.6
285 (C-1'), 33.0 (C-2'), 128.5 (C-3'), 129.1 (C-4'), 114.4 (C-5'), 155.2 (C-6'), 114.4 (C-7'),
286 129.1 (C-8'), 98.7 (glc-1"), 72.7 (glc-2"), 75.8 (glc-3"), 69.5 (glc-4"), 76.1 (glc-5"),
287 61.0 (glc-6"). Those data were in agreement with earlier published data for
288 Ligstroside²³.

289 Hydroxytyrosol (C): a yellow gum, ¹H-NMR (CD₃COCD₃): δ 6.65 (m, 2H, H-2, 5),
290 6.51(d, 1H, *J* = 8.0, 2.0 Hz, H-6), 2.64 (t, 2H, *J* = 7.2 Hz, H-7), 3.65 (t, 2H, *J* = 7.6 Hz,
291 H-8); ¹³C-NMR (CD₃COCD₃): δ 130.0 (C, C-1), 114.3 (CH, C-2), 144.0 (C, C-3),
292 142.5 (C, C-4), 115.2 (CH, C-5), 119.3 (CH, C-6), 37.9 (CH₂, C-7), 62.6 (CH₂, C-8) .
293 Those data were in agreement with earlier published data for Hydroxytyrosol²⁴.

294 Tyrosol (D): a yellow gum, ¹H-NMR (CD₃COCD₃): δ 6.71 (d, 2H, *J* = 6.4, 2.4 Hz,
295 H-3, 5), 7.01 (d, 2H, *J* = 6.4, 2.4 Hz, H-2, 6), 3.63 (t, 2H, *J* = 7.2 Hz, H-8), 2.67 (t, 2H,
296 *J* = 7.2 Hz, H-7); ¹³C-NMR (CD₃COCD₃): δ 155.6 (C, C-4), 114.9(CH, C-3,5),
297 129.8(CH, C-2,6), 129.7(C, C-1), 63.2 (CH₂, C-8), 38.5 (CH₂, C-7) . Those data were
298 in agreement with earlier published data for Tyrosol²⁴.

299 Luteolin-7-O-β-D-glucoside (E): a yellow powder, ¹H-NMR (DMSO-d₆): δ 7.95 (d,
300 2H, *J* = 8.8 Hz, H-2', 6'), 6.92 (d, 2H, *J* = 8.8 Hz, H-3', 5'), 6.87 (s, 1H, H-3), 6.82 (d,
301 1H, *J* = 2.0Hz, H-8), 6.43 (d, 1H, *J* = 2.0Hz, H-6), 3.15-5.43 (H-Glc); ¹³C-NMR
302 (DMSO-d₆): δ 164.3 (C-2), 103.2 (C-3) , 181.9 (C-4), 161.1 (C-5), 99.5 (C-6) , 162.9
303 (C-7), 94.7 (C-8) , 156.9 (C-9) , 105.3 (C-10) , 121.4 (C-1'), 113.5 (C-2') , 145.8
304 (C-3') , 149.9 (C-4') , 116.0 (C-5') , 119.2 (C-6'), 99.7 (glu-1) , 73.1 (glu-2) , 76.4
305 (glu-3), 69.5 (glu-4) , 77.1 (glu-5) , 60.6 (glu-6). Those data were in agreement with

306 earlier published data for Luteolin-7-O- β -D-glucoside²⁵.

307 And the compounds A-E were further analyzed on HPLC to determine their purities.

308 The purities of Oleuropein, Ligstroside, Hydroxytyrosol, Tyrosol and

309 Luteolin-7-O- β -D-glucoside elution peaks were 91, 93, 87, 89 and 82%, respectively

310 assessed by HPLC at 280 nm.

311 **3 Results and Discussion**

312 **3.1 Anti-diabetic activity**

313 The inhibition activity of carbohydrate hydrolyzing enzymes in the human digestive

314 tract is regarded as an effective method for the control of diabetes by diminishing the

315 absorption of glucose decomposed from starch by these enzymes. Therefore, effective

316 and nontoxic inhibitors of α -amylase have long been sought. The purified six fractions

317 from the olive leaves by resin AB-8 were screened for their anti-diabetic activities by

318 the α -amylase assay, which is widely used to evaluate the anti-diabetic activities of

319 natural products. The result is summarized in Tab. 1. IC₅₀ values of the I, III, IV,

320 V and VI against α -amylase was 249.0, 49.3, 34.1, 55.0 and 39.3 mg/mL,

321 respectively. The fraction II showed relative weak anti-diabetic activity with IC₅₀>

322 250 mg/mL. The results suggested that water/ethanol elution parts displayed the

323 anti-diabetic activity against α -amylase and fraction IV showed stronger inhibitory

324 activity than others.

325 Tab. 1 Results of inhibitory rates on α -amylase of different fractions ($\bar{x} \pm s$, n=3)

Inhibition rate (%)	Concentration (mg/mL)							
	30	40	50	60	70	80	90	100

Fraction I	26.1±1.4	26.5±0.8	28.6±1.1	29.5±1.3	31.8±0.5	36.6±2.1	38.1±1.8	38.8±1.6
Fraction II	5.6±0.3	6.3±0.2	7.3±0.4	6.8±0.3	5.9±0.3	7.5±0.4	8.1±0.3	8.1±0.3
Fraction III,	27.5±0.8	36.4±0.6	48.0±2.6	54.5±2.3	66.7±2.8	75.6±4.3	85.6±1.3	87.7±2.6
Fraction IV	57.5±0.3	60.0±0.8	65.5±2.1	70.0±0.8	74.4±1.0	85.2±1.2	93.9±1.8	96.9±2.8
Fraction V	19.5±1.0	35.8±1.1	45.9±0.5	55.3±1.3	60.9±1.1	68.7±3.6	72.9±2.2	80.9±1.8
Fraction VI	42.6±0.7	54.4±1.0	59.7±1.0	65.1±1.2	72.7±1.4	79.6±0.9	93.2±0.3	94.7±1.2

326

327 **3.2 Optimization of HSCCC conditions for separation of the anti-diabetic**
328 **fraction**

329 The optimum of the separation conditions for HSCCC is related to various parameters
330 including a two-phase solvent system, flow rate, revolution speed, column
331 temperature, et al. An appropriate solvent system providing a suitable range of the
332 partition coefficients (K) for target compounds is the key to a successful HSCCC
333 separation. As previously reported, for effective separations with regard to resolution
334 and short elution time, partition coefficient (K) at the range of $0.5 < K < 2$ is required. If
335 the K value is too low, the target peak won't properly separate from other peaks; if the
336 K value is too high, it will lead to long run times and the consumption of excessive
337 solvent. In order to obtain the optimal two-phase solvent system for the separation,
338 the HEMWat solvent was chosen to be tested. HEMWat is a classic two-phase solvent
339 system because it provides a broad polarity range²⁶. In this experiment, the K values
340 of the target compounds in different ratios of HEMWat were determined by HPLC
341 and listed in Table 2. The large differences of K values in different HEMWat solvent

342 systems showed that the target compounds covered a wide polarity range, indicating
 343 that it was impossible to separate them with a conventional HSCCC method. Thus, we
 344 developed two steps to separate the target compounds with HSCCC. In order to select
 345 the optimum two-phase solvent system, a series of tests were performed in this study.
 346 According to the rules of selecting the optimal conditions, in the first step, several
 347 types of the solvent systems composed of ethyl acetate–n-butanol–water at different
 348 volume ratios were chosen. The measured K values were summarized in Tab 2. It was
 349 found that ethyl acetate–water (1:1 v/v) solvent system provided suitable K values for
 350 the target compounds because of their K values being in the range 0.5-2 allowing
 351 efficient separation within a comfortable running time.

352 As it is difficult to isolate all polar compounds from the extraction, we chose the
 353 fraction 1 which was admixture obtained from the first step for further separation in
 354 the second step. In order to obtain significant differences in the K values, in this
 355 step, the same measured method for K values was used, and butanol–water–acetic
 356 acid (1:1:0.1 v/v/v) was used as the K values were obvious and helpful for obtaining
 357 good separation of the compounds (Tab. 3).

358 Tab. 2 The K values of HSCCC solvent system in the first step

NO.	Extraction solvent	K values			
		K_a	K_b	K_c	K_d
1	Heotane–EtOAc–MeOH–Water (1:6:1:6)	0.1	0.23	0.40	0.29
2	Heotane–EtOAc–MeOH–Water (1:9:1:9)	0.36	0.37	0.67	1.7
3	Heotane–EtOAc–MeOH–Water (1:19:1:19)	0.41	0.53	1.24	0.36

4	EtOAc–Water (1:1)	0.66	0.74	1.45	0.52
5	EtOAc–MeOH–Water (4:1:5)	10.6	>10	>10	>10

359

360

Tab. 3 The K values of HSCCC solvent system in the second step

NO.	Extraction solvent	K values							
		K_e	K_f	K_g	K_h	K_i	K_j	K_k	K_l
1	EtOAc–Butanol–water (2:3:5)	0.69	0.41	0.12	0.89	8.05	4.28	2.02	4.27
2	Butanol–water (1:1)	0.36	1.13	0.31	0.59	5.20	3.08	1.64	3.97
3	Butanol–water–acetic acid (1:1:0.1)	0.47	1.72	0.22	0.60	0.58	1.43	0.76	0.68
4	Butanol–water–acetic acid (1:1:0.3)	0.53	0.81	0.49	0.62	1.59	1.99	0.90	2.05

361

The high flow rate of the mobile phase shortened the separation time, while the low

362

flow rate phase improved the resolution. HSCCC was carried out by using the upper

363

layer of solvent as the stationary phase and the lower layer of solvent as the mobile

364

phase. Based on the preliminary experiment, the flow rate and rotation speed were

365

optimized, where a flow rate of 4.8 mL/min combined with a rotation speed of 1400

366

rpm in the first step resulted in a good separation of sample within a decent time

367

period (200 min). In the second step, the separation was achieved at a flow rate of 3.0

368

mL/min combined with a rotation speed of 1500 rpm and resulted in a good

369

separation of sample within a decent time period (100 min). Under the optimized

370

conditions, the compounds were separated from the sample solution with the


371 concentration 20 mg/mL.

372

373 **3.3 Evaluation of specific antioxidants in natural products by post-column**
374 **on-line HSCCC with α -amylase anti-diabetic assay**

375 Recently, on-line HPLC with DPPH radical scavenging assay has been focused on the
376 screening of specific antioxidants from various samples such as espresso coffees,
377 olive leaf, and non-polar food matrixes²⁷. This method was useful to indicate
378 unknown antioxidants from natural products and foods. However, on-line HPLC with
379 DPPH radical scavenging assay has disadvantages that these targets of anti-oxidative
380 activity could not be purified for the identification and/or evaluation of unknown
381 compounds by NMR, *in vivo*, and *in vitro* assays. Thus, in order to discover the
382 anti-diabetic compounds, we developed a novel strategy using post-column on-line
383 HSCCC with α -amylase anti-diabetic assay. It would be a valid and feasible way for
384 screening unknown anti-diabetes from the leaves of *Olea europaea* L. Consequently,
385 the first step of post-column on-line HSCCC with α -amylase anti-diabetic assay was
386 adding 0.15 mL α -amylase to the each sample collection tubes behind column of
387 HSCCC. Then the HSCCC separated the fraction IV with the optimal two-phase
388 solvent system. The effluent from the tail end of the column was continuously

389 monitored at 280 nm with the UV detector and fraction collection was started at the
 390 time of injection. Fractions were collected according to their composition in the
 391 column with α -amylase. Following reaction for 10 min, 0.4 mL of soluble starch
 392 (0.4%, w/v) in 25 mmol/L sodium phosphate buffer (pH7.0) was added. It was carried
 393 out for 10 min and terminated by addition of 0.3 mL of HCl solution (1.0 mol/L), then
 394 add 0.2 mL Iodine solution to have color. The absorbance was measured at 660 nm by
 395 UV detection. The same method was used in the second process. The method showed
 396 that a very useful and efficient purification method for specific anti-diabetes from
 397 olive leaves was developed by HSCCC using the simple two-phase solvent system.
 398 These results were shown in Fig.2. We can see peak a and d (compound A, B) in the
 399 first step and peak f, g and l (compound C, D and E) showed the anti-diabetic activity.



400
 401 Fig. 2 HSCCC chromatogram of fraction IV HSCCC chromatogram of fraction 1

402

403 4 Conclusions

404 In this study, we successfully applied the novel high speed counter-current

405 chromatography (HSCCC) coupled with post-column on-line evaluation method to
406 the rapidly and efficient screening five major anti-diabetic compounds from the leaves
407 of *Olea europaea* L. with acceptable purity. The results of the study demonstrated that
408 it is a powerful method for separation and it can reduce the time taken to obtain the
409 target compounds because the separation would be achieved under the guidance of
410 on-line evaluation with potential anti-diabetic activity. Meanwhile, this method
411 provided an instructive pattern for screening and identifying active substance in
412 herbal medicines.

413

414 **5 Acknowledgments**

415 We express our appreciation to the support of the National Natural Science
416 Foundation of China (NSFC No. 20775083 and No. 21175142), West Light
417 Foundation of The Chinese Academy of Science and Open Fund of Key Laboratory
418 of Chemistry of Northwestern Plant Resources of The Chinese Academy of Science
419 (No. CNPR-2011kft-02).

420

421 **References**

- 422 [1] A. Trichopoulou, T. Costacou, C. Bamia and D. Trichopoulos, *N. Engl. J. Med.*,
423 2003, **348**, 2599-2608.
- 424 [2] A. Procopio, S. Alcaro and M. Nardi, *J. agric. Food Chem.*, 2009, **57**,
425 11161-11167.
- 426 [3] M. J. Amiot, A. Fleuriet and J. J. Macheix, *J. Agric. Food Chem.*, 1986, **34**,

- 427 823-826.
- 428 [4] M. Brenes, A. Garcia, P. Garcia, J. J. Rios and A. Garrido, *J. Agric. Food Chem.*,
429 1999, **47**, 3535-3540.
- 430 [5] C. Savournin, B. Baghdikian and R. Ellas, *J. Agric. Food Chem.*, 2001, **49**,
431 618-621.
- 432 [6] C. Li, Y. Zheng, X. Wang, S. Feng and D. Di, *J. Sci. Food Agric.*, 2011; **91**,
433 2826-2834.
- 434 [7] G. O. Benavente, J. Castillo, J. Lorente, A. Orturio and J. A. Del Rio, *Food Chem.*,
435 2000, **68**, 457-462.
- 436 [8] N. Nenadis and M. Z. Tsimidou, *Recent Prog. Med. Plants*, 2009, **25**, 53-74.
- 437 [9] A. S. Boath, D. Stewart and G. J. McDougall, *Food Chem.*, 2012, **135**, 929-936.
- 438 [10] P. Zimmet, K. Alberti and J. Shaw, *Nature*, 2001, **414**, 782-787.
- 439 [11] A. D. Baron, *Diabetes Res. Clin. Pr.*, 1998, **40**, S51-S55.
- 440 [12] M. R. Bhandari, N. Jong-Anurakkun, G. Hong and J. Kawabata, *Food Chem.*,
441 2008, **106**, 247-252.
- 442 [13] N. Saito, H. Sakai, H. Sekihara and Y. Yajima, *J. Int. Med. Res.*, 1998, **26**,
443 219-232.
- 444 [14] D. Grussu, D. Stewart and G. J. McDougall, *J. Agric. Food Chem.*, 2011, **59**,
445 2324-2331.
- 446 [15] H. Wang, Y. J. Du and H. C. Sun, *Food Chem.*, 2010, **123**, 6-13.
- 447 [16] J. Xiao, J. Huo, H. Jiang and F. Yang, *Int. J. Biol. Macromol.*, 2011, **49**,
448 1143-1151.

- 449 [17] Z. Yu, Y. Yin, W. Zhao, J. Liu and F. Chen, *Food Chem.*, 2012, **135**, 2078-2085.
- 450 [18] Y. Liu, G. Wang, X. Huang, Y. Liu and D. Di, *New J. Chem.*, 2014, DOI:
451 10.1039/C3NJ01140B.
- 452 [19] X. Huang, J. Fu and D. Di, *Sep. Purif. Technol.*, 2010, **71**, 220-224.
- 453 [20] Z. Yu, Y. Yin, W. Zhao, F. Wang, Y. Yu, B. Liu, J. Liu and F. Chen, *J. Food Sci.*,
454 2011, **76**, C1149-C1155.
- 455 [21] Z. Yu, Y. Yin, Y. Yu, B. Liu, J. Liu and F. Chen, *Food Chem.*, 2011, **129**,
456 1376-1382.
- 457 [22] H. Kuwajima, T. Vetuira, K. Takaishi, K. Inouye and H. Inouye, *Phytochemistry*,
458 1988, **27**, 1757-1759.
- 459 [23] P. Gariboldi, G. Jommi and L. Verotta, *Phytochemistry*, 1986, **25**, 865-869.
- 460 [24] Robert W. Owen, Walter Mier, Attilio Giacosa, William E. Hull, Bertold
461 Spiegelhalder and Helmut Bartsch, *Clin. Chem.*, 2000, **46**, 976-988.
- 462 [25] F. Tomas and F. Ferreres, *An. Quim. Ser. C*, 1980, **76**, 292-293.
- 463 [26] Z. Feng, X. Chen and D. Di, *J. Sep. Sci.*, 2012, **35**, 625-632.
- 464 [27] X. Wang, C. Li, Y. Liu, H. Li and D. Di, *Biomed. Chromatogr.*, 2011, **35**,
465 373-380.